1: Location of various mediastinal masses based on radioimaging
anterior mediastinum 24 (80%) posterious mediastinum 4 (13%) middle mediastinum 2 (7%) Note: Table made from pie chart.
Clinical and Radioimaging
Characteristics of Neurognathostomiasis and Intraocular Gnathostomiasis (Adapted from Katchanov J et al 7, and Pillai GS et al) Neurological CNS entry access for Clinical neurological & And ocular infective third stage ophthalmological syndromes (L3) larvae presentations Radiculomyelitis/ Intervertebral Radiculopathy; spinal Myeloencephalitis foramina along spinal syndrome (paraplegia, nerves & vessels neurogenic bladder, quadriplegia); may progress to myeloencephalitis.
PHILADELPHIA -- The radioimaging
agent 18F-florbetaben reliably excluded amyloid pathology in a study of 74 end-of-life patients with dementia.
was suggestive of a mass in both parapharyngeal spaces; the lesion was more prominent on the left side.
Not surprisingly, lungs of healthy individuals display no uptake of folate-targeted radioimaging
agents, whereas lungs of many cancer patients display localized uptake at sites of malignant disease.
The primary diagnosis of extracranial meningioma is difficult even on advanced radioimaging
techniques like CT and MRI .
application used for body scans is expected to enter clinical trials this fall, and an optical imaging application used to measure prostate cancer cells in blood samples is already in clinical trials.
Thromboview is a blood clot radioimaging
antibody reagent, which uses radiolabelled antibodies to locate blood clots in the body.
BLSI's products in development include: Altropane, a radioimaging
agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; fusion toxins for the treatment of cancer and multiple sclerosis; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.
of melanoma using 99 mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen.
In addition to patents covering certain antibodies, including reengineered forms, Immunomedics holds numerous broad patents in the area of disease targeting, imaging and therapy (including cancer, infectious and cardiovascular diseases), radiolabeled antibodies and fragments, pre-targeting methods for imaging and therapy, neutron-capture therapy of cancer, intraoperative and laparoscopic probe technology with radioimaging
agents, magnetic-resonance imaging with specific antibodies, positron-emission tomography with specific antibodies, radioimmunotherapy with anti-idiotype antibodies and other vaccine approaches.
Initiated a Phase 1 clinical trial for the molecular radioimaging
program for the detection and monitoring of metastatic prostate cancer.